Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENE-T: Orca-T in AML or MDS Following RIC or NMA Conditioning
NCT07216443Phase 2Recruiting
- Sponsor
- Orca Bio
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of regulatory T-cell enriched infusion in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL), sponsored by Orca Bio. Started Dec 2025; status: recruiting.
02
Drugs
regulatory T-cell enriched infusion
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07216443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216443.